Add to ORKGWe lack tools to risk-stratify triple-negative breast cancer (TNBC). Our goal was to develop molecular tools to predict disease recurrence. Methylation array analysis was performed on 110 samples treated by locoregional therapy obtained from institutional cohorts. Discovered marker sets were then tested by Kaplan-Meier analyses in a prospectively collected TNBC cohort of 49 samples from the no-chemotherapy arms of IBCSG trials VIII and IX, and by logistic regression in a chemotherapy-treated cohort of 121 TNBCs from combined IBCSG trials and institutional repositories. High methylation was associated with shorter recurrence-free interval in the no-chemotherapy arm of the IBCSG studies, as well as in the chemotherapy-treated patients within ...
Epigenetic alterations measured in blood may help guide breast cancer treatment. The multisite prosp...
The identification of molecular markers in negative surgical margins of oral squamous cell carcinoma...
Background: PITX2 DNA methylation has been shown to predict outcomes in high-risk breast cancer pati...
We lack tools to risk-stratify triple-negative breast cancer (TNBC). Our goal was to develop molecul...
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer (BC) subtype and lacks tar...
Purpose: We have shown that DNA methylation of the PITX2 gene predicts risk of distant recurrence in...
Triple-negative breast cancer (TNBC) constitutes a heterogeneous breast cancer subgroup with poor pr...
<div><p>Breast cancer has various molecular subtypes and displays high heterogeneity. Aberrant DNA m...
Abstract Background Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in tri...
Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype with no targeted t...
Background Locally advanced breast cancer is a heterogeneous disease with respect to response to ne...
This thesis project is motivated by the urgent needs of biomarkers for characterizing the triple neg...
Abnormal DNA methylation is well established for breast cancer and contributes to its progression by...
Background Predictive factors of benefit from specific chemotherapy regimens are not currently avail...
Epigenetic alterations in the cancer methylome are common in breast cancer and provide novel options...
Epigenetic alterations measured in blood may help guide breast cancer treatment. The multisite prosp...
The identification of molecular markers in negative surgical margins of oral squamous cell carcinoma...
Background: PITX2 DNA methylation has been shown to predict outcomes in high-risk breast cancer pati...
We lack tools to risk-stratify triple-negative breast cancer (TNBC). Our goal was to develop molecul...
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer (BC) subtype and lacks tar...
Purpose: We have shown that DNA methylation of the PITX2 gene predicts risk of distant recurrence in...
Triple-negative breast cancer (TNBC) constitutes a heterogeneous breast cancer subgroup with poor pr...
<div><p>Breast cancer has various molecular subtypes and displays high heterogeneity. Aberrant DNA m...
Abstract Background Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in tri...
Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype with no targeted t...
Background Locally advanced breast cancer is a heterogeneous disease with respect to response to ne...
This thesis project is motivated by the urgent needs of biomarkers for characterizing the triple neg...
Abnormal DNA methylation is well established for breast cancer and contributes to its progression by...
Background Predictive factors of benefit from specific chemotherapy regimens are not currently avail...
Epigenetic alterations in the cancer methylome are common in breast cancer and provide novel options...
Epigenetic alterations measured in blood may help guide breast cancer treatment. The multisite prosp...
The identification of molecular markers in negative surgical margins of oral squamous cell carcinoma...
Background: PITX2 DNA methylation has been shown to predict outcomes in high-risk breast cancer pati...